HIV Drugs Market By Medication Class, By Distribution Channel : Global Opportunity Analysis and Industry Forecast, 2023-2032

Description

List of Tables

According to a new report published by Allied Market Research, titled, "HIV Drugs Market," The hiv drugs market was valued at $32.8 billion in 2022, and is estimated to reach $51.1 billion by 2032, growing at a CAGR of 4.5% from 2023 to 2032. Human immunodeficiency virus (HIV) is a type of infection that attacks the immune system of the body. It weakens the body and makes it easier to get sick with any diseases. The antiretroviral drugs (HIV drugs) such as nucleoside reverse transcriptase inhibitors (NRTIs), protease inhibitors (PIs), entry inhibitors, HIV integrase strand transfer inhibitors and others are used for the treatment of HIV.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)

Go To Market Strategy
Market share analysis of players by products/segments
New Product Development/ Product Matrix of Key Players
Additional company profiles with specific to client's interest
Average Selling Price Analysis / Price Point Analysis
Brands Share Analysis
Criss-cross segment analysis- market size and forecast
Historic market data
Key player details (including location, contact details, supplier/vendor network etc. in excel format)
SWOT Analysis

Key Market Segments

By Medication Class

Multi-Class Combination Drugs
- Brand
- Atripla
- Complera
- Prezcobix
- Stribild
- Genvoya
- Odefsey
- Symtuza
- Triumeq
- Descovy
- Dovato
- Others
Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
- Brand
- Emtriva
- Epivir
- Epzicom/Kivexa
- Truvada
- Biktarvy
- Others
Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
- Brand
- Edurant
- Others
Protease Inhibitors (PIs)
- Brand
- Aptivus
- Kaletra
- Lexiva/ Telzir
- Norvir
- Viracept
- Others
Entry Inhibitors
- Brand
- Selzentry
- Fuzeon
- Rukobia
HIV Integrase Strand Transfer Inhibitors
- Brand
- Isentress/Isentress HD
- Tivicay
- Apretude
- Juluca
Others

By Distribution Channel

Hospital Pharmacies
Drugs stores and retail pharmacies
Online pharmacies

By Region

North America
- U.S.
- Canada
- Mexico
Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
Asia-Pacific
- Japan
- China
- Australia
- India
- South Korea
- Rest of Asia-Pacific
LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA

Key Market Players:

Merck & Co., Inc.
Cipla Ltd.
F. Hoffmann-La Roche Ltd.
Bristol-Myers Squibb Company
Gilead Sciences, Inc.
AbbVie Inc.
Boehringer Ingelheim International GmbH
Teva Pharmaceutical Industries Ltd.
GlaxoSmithKline plc
Johnson & Johnson

Product Code: A01537

CHAPTER 1: INTRODUCTION

1.1. Report description
1.2. Key market segments
1.3. Key benefits to the stakeholders
1.4. Research methodology
- 1.4.1. Primary research
- 1.4.2. Secondary research
- 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

2.1. CXO Perspective

CHAPTER 3: MARKET OVERVIEW

3.1. Market definition and scope
3.2. Key findings
- 3.2.1. Top impacting factors
- 3.2.2. Top investment pockets
3.3. Porter's five forces analysis
- 3.3.1. Low bargaining power of suppliers
- 3.3.2. Low threat of new entrants
- 3.3.3. Low threat of substitutes
- 3.3.4. Low intensity of rivalry
- 3.3.5. Low bargaining power of buyers
3.4. Market dynamics
- 3.4.1. Drivers
  - 3.4.1.1. Rise in cases of HIV
  - 3.4.1.2. Initiatives taken by various government associations to raise awareness about diagnosis and management of HIV/AIDS
  - 3.4.1.3. Introduction of generic drugs for HIV
- 3.4.2. Restraints
  - 3.4.2.1. Stringent regulatory requirements for the approval and commercialization of HIV drugs
- 3.4.3. Opportunities
  - 3.4.3.1. Increasing number of products in the pipeline

CHAPTER 4: HIV DRUGS MARKET, BY MEDICATION CLASS

4.1. Overview
- 4.1.1. Market size and forecast
4.2. Multi-Class Combination Drugs
- 4.2.1. Key market trends, growth factors and opportunities
- 4.2.2. Market size and forecast, by region
- 4.2.3. Market share analysis by country
- 4.2.4. Multi-Class Combination Drugs HIV Drugs Market by Brand
4.3. Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
- 4.3.1. Key market trends, growth factors and opportunities
- 4.3.2. Market size and forecast, by region
- 4.3.3. Market share analysis by country
- 4.3.4. Nucleoside Reverse Transcriptase Inhibitors (NRTIs) HIV Drugs Market by Brand
4.4. Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
- 4.4.1. Key market trends, growth factors and opportunities
- 4.4.2. Market size and forecast, by region
- 4.4.3. Market share analysis by country
- 4.4.4. Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) HIV Drugs Market by Brand
4.5. Protease Inhibitors (PIs)
- 4.5.1. Key market trends, growth factors and opportunities
- 4.5.2. Market size and forecast, by region
- 4.5.3. Market share analysis by country
- 4.5.4. Protease Inhibitors (PIs) HIV Drugs Market by Brand
4.6. Entry Inhibitors
- 4.6.1. Key market trends, growth factors and opportunities
- 4.6.2. Market size and forecast, by region
- 4.6.3. Market share analysis by country
- 4.6.4. Entry Inhibitors HIV Drugs Market by Brand
4.7. HIV Integrase Strand Transfer Inhibitors
- 4.7.1. Key market trends, growth factors and opportunities
- 4.7.2. Market size and forecast, by region
- 4.7.3. Market share analysis by country
- 4.7.4. HIV Integrase Strand Transfer Inhibitors HIV Drugs Market by Brand
4.8. Others
- 4.8.1. Key market trends, growth factors and opportunities
- 4.8.2. Market size and forecast, by region
- 4.8.3. Market share analysis by country

CHAPTER 5: HIV DRUGS MARKET, BY DISTRIBUTION CHANNEL

5.1. Overview
- 5.1.1. Market size and forecast
5.2. Hospital Pharmacies
- 5.2.1. Key market trends, growth factors and opportunities
- 5.2.2. Market size and forecast, by region
- 5.2.3. Market share analysis by country
5.3. Drugs stores and retail pharmacies
- 5.3.1. Key market trends, growth factors and opportunities
- 5.3.2. Market size and forecast, by region
- 5.3.3. Market share analysis by country
5.4. Online pharmacies
- 5.4.1. Key market trends, growth factors and opportunities
- 5.4.2. Market size and forecast, by region
- 5.4.3. Market share analysis by country

CHAPTER 6: HIV DRUGS MARKET, BY REGION

6.1. Overview
- 6.1.1. Market size and forecast By Region
6.2. North America
- 6.2.1. Key market trends, growth factors and opportunities
- 6.2.2. Market size and forecast, by Medication Class
- 6.2.3. Market size and forecast, by Distribution Channel
- 6.2.4. Market size and forecast, by country
  - 6.2.4.1. U.S.
  - 6.2.4.1.1. Market size and forecast, by Medication Class
  - 6.2.4.1.2. Market size and forecast, by Distribution Channel
  - 6.2.4.2. Canada
  - 6.2.4.2.1. Market size and forecast, by Medication Class
  - 6.2.4.2.2. Market size and forecast, by Distribution Channel
  - 6.2.4.3. Mexico
  - 6.2.4.3.1. Market size and forecast, by Medication Class
  - 6.2.4.3.2. Market size and forecast, by Distribution Channel
6.3. Europe
- 6.3.1. Key market trends, growth factors and opportunities
- 6.3.2. Market size and forecast, by Medication Class
- 6.3.3. Market size and forecast, by Distribution Channel
- 6.3.4. Market size and forecast, by country
  - 6.3.4.1. Germany
  - 6.3.4.1.1. Market size and forecast, by Medication Class
  - 6.3.4.1.2. Market size and forecast, by Distribution Channel
  - 6.3.4.2. France
  - 6.3.4.2.1. Market size and forecast, by Medication Class
  - 6.3.4.2.2. Market size and forecast, by Distribution Channel
  - 6.3.4.3. UK
  - 6.3.4.3.1. Market size and forecast, by Medication Class
  - 6.3.4.3.2. Market size and forecast, by Distribution Channel
  - 6.3.4.4. Italy
  - 6.3.4.4.1. Market size and forecast, by Medication Class
  - 6.3.4.4.2. Market size and forecast, by Distribution Channel
  - 6.3.4.5. Spain
  - 6.3.4.5.1. Market size and forecast, by Medication Class
  - 6.3.4.5.2. Market size and forecast, by Distribution Channel
  - 6.3.4.6. Rest of Europe
  - 6.3.4.6.1. Market size and forecast, by Medication Class
  - 6.3.4.6.2. Market size and forecast, by Distribution Channel
6.4. Asia-Pacific
- 6.4.1. Key market trends, growth factors and opportunities
- 6.4.2. Market size and forecast, by Medication Class
- 6.4.3. Market size and forecast, by Distribution Channel
- 6.4.4. Market size and forecast, by country
  - 6.4.4.1. Japan
  - 6.4.4.1.1. Market size and forecast, by Medication Class
  - 6.4.4.1.2. Market size and forecast, by Distribution Channel
  - 6.4.4.2. China
  - 6.4.4.2.1. Market size and forecast, by Medication Class
  - 6.4.4.2.2. Market size and forecast, by Distribution Channel
  - 6.4.4.3. Australia
  - 6.4.4.3.1. Market size and forecast, by Medication Class
  - 6.4.4.3.2. Market size and forecast, by Distribution Channel
  - 6.4.4.4. India
  - 6.4.4.4.1. Market size and forecast, by Medication Class
  - 6.4.4.4.2. Market size and forecast, by Distribution Channel
  - 6.4.4.5. South Korea
  - 6.4.4.5.1. Market size and forecast, by Medication Class
  - 6.4.4.5.2. Market size and forecast, by Distribution Channel
  - 6.4.4.6. Rest of Asia-Pacific
  - 6.4.4.6.1. Market size and forecast, by Medication Class
  - 6.4.4.6.2. Market size and forecast, by Distribution Channel
6.5. LAMEA
- 6.5.1. Key market trends, growth factors and opportunities
- 6.5.2. Market size and forecast, by Medication Class
- 6.5.3. Market size and forecast, by Distribution Channel
- 6.5.4. Market size and forecast, by country
  - 6.5.4.1. Brazil
  - 6.5.4.1.1. Market size and forecast, by Medication Class
  - 6.5.4.1.2. Market size and forecast, by Distribution Channel
  - 6.5.4.2. Saudi Arabia
  - 6.5.4.2.1. Market size and forecast, by Medication Class
  - 6.5.4.2.2. Market size and forecast, by Distribution Channel
  - 6.5.4.3. South Africa
  - 6.5.4.3.1. Market size and forecast, by Medication Class
  - 6.5.4.3.2. Market size and forecast, by Distribution Channel
  - 6.5.4.4. Rest of LAMEA
  - 6.5.4.4.1. Market size and forecast, by Medication Class
  - 6.5.4.4.2. Market size and forecast, by Distribution Channel

CHAPTER 7: COMPETITIVE LANDSCAPE

7.1. Introduction
7.2. Top winning strategies
7.3. Product mapping of top 10 player
7.4. Competitive dashboard
7.5. Competitive heatmap
7.6. Top player positioning, 2022

CHAPTER 8: COMPANY PROFILES

8.1. AbbVie Inc.
- 8.1.1. Company overview
- 8.1.2. Key executives
- 8.1.3. Company snapshot
- 8.1.4. Operating business segments
- 8.1.5. Product portfolio
- 8.1.6. Business performance
8.2. Merck & Co., Inc.
- 8.2.1. Company overview
- 8.2.2. Key executives
- 8.2.3. Company snapshot
- 8.2.4. Operating business segments
- 8.2.5. Product portfolio
- 8.2.6. Business performance
- 8.2.7. Key strategic moves and developments
8.3. Boehringer Ingelheim International GmbH
- 8.3.1. Company overview
- 8.3.2. Key executives
- 8.3.3. Company snapshot
- 8.3.4. Operating business segments
- 8.3.5. Product portfolio
- 8.3.6. Business performance
8.4. Gilead Sciences, Inc.
- 8.4.1. Company overview
- 8.4.2. Key executives
- 8.4.3. Company snapshot
- 8.4.4. Operating business segments
- 8.4.5. Product portfolio
- 8.4.6. Business performance
- 8.4.7. Key strategic moves and developments
8.5. GlaxoSmithKline plc
- 8.5.1. Company overview
- 8.5.2. Key executives
- 8.5.3. Company snapshot
- 8.5.4. Operating business segments
- 8.5.5. Product portfolio
- 8.5.6. Business performance
- 8.5.7. Key strategic moves and developments
8.6. Johnson & Johnson
- 8.6.1. Company overview
- 8.6.2. Key executives
- 8.6.3. Company snapshot
- 8.6.4. Operating business segments
- 8.6.5. Product portfolio
- 8.6.6. Business performance
- 8.6.7. Key strategic moves and developments
8.7. F. Hoffmann-La Roche Ltd.
- 8.7.1. Company overview
- 8.7.2. Key executives
- 8.7.3. Company snapshot
- 8.7.4. Operating business segments
- 8.7.5. Product portfolio
- 8.7.6. Business performance
8.8. Teva Pharmaceutical Industries Ltd.
- 8.8.1. Company overview
- 8.8.2. Key executives
- 8.8.3. Company snapshot
- 8.8.4. Operating business segments
- 8.8.5. Product portfolio
- 8.8.6. Business performance
8.9. Cipla Ltd.
- 8.9.1. Company overview
- 8.9.2. Key executives
- 8.9.3. Company snapshot
- 8.9.4. Operating business segments
- 8.9.5. Product portfolio
- 8.9.6. Business performance
8.10. Bristol-Myers Squibb Company
- 8.10.1. Company overview
- 8.10.2. Key executives
- 8.10.3. Company snapshot
- 8.10.4. Operating business segments
- 8.10.5. Product portfolio
- 8.10.6. Business performance